FR3082425B1 - Composition pour utilisation dans le traitement de l'osteopenie et / ou de l'osteoporose - Google Patents

Composition pour utilisation dans le traitement de l'osteopenie et / ou de l'osteoporose Download PDF

Info

Publication number
FR3082425B1
FR3082425B1 FR1870717A FR1870717A FR3082425B1 FR 3082425 B1 FR3082425 B1 FR 3082425B1 FR 1870717 A FR1870717 A FR 1870717A FR 1870717 A FR1870717 A FR 1870717A FR 3082425 B1 FR3082425 B1 FR 3082425B1
Authority
FR
France
Prior art keywords
composition
osteopenia
osteoporosis
treatment
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1870717A
Other languages
English (en)
Other versions
FR3082425A1 (fr
Inventor
Guy Wyvekens
Francois Motte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eos Laboratory Be Srl
Original Assignee
Normaphar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Normaphar filed Critical Normaphar
Priority to FR1870717A priority Critical patent/FR3082425B1/fr
Publication of FR3082425A1 publication Critical patent/FR3082425A1/fr
Application granted granted Critical
Publication of FR3082425B1 publication Critical patent/FR3082425B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger

Abstract

La présente invention porte sur une composition comprenant un extrait de curcuma, du calcium et de la vitamine D pour utilisation dans le traitement de l'ostéopénie et/ou de l'ostéoporose, ladite composition comprenant ledit calcium au moins sous forme de glycérophosphate de calcium.
FR1870717A 2018-06-18 2018-06-18 Composition pour utilisation dans le traitement de l'osteopenie et / ou de l'osteoporose Active FR3082425B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1870717A FR3082425B1 (fr) 2018-06-18 2018-06-18 Composition pour utilisation dans le traitement de l'osteopenie et / ou de l'osteoporose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1870717 2018-06-18
FR1870717A FR3082425B1 (fr) 2018-06-18 2018-06-18 Composition pour utilisation dans le traitement de l'osteopenie et / ou de l'osteoporose

Publications (2)

Publication Number Publication Date
FR3082425A1 FR3082425A1 (fr) 2019-12-20
FR3082425B1 true FR3082425B1 (fr) 2020-09-11

Family

ID=63684187

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1870717A Active FR3082425B1 (fr) 2018-06-18 2018-06-18 Composition pour utilisation dans le traitement de l'osteopenie et / ou de l'osteoporose

Country Status (1)

Country Link
FR (1) FR3082425B1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515508A (ja) * 2000-12-16 2004-05-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 化合物の健康促進組成物
US20030190381A1 (en) * 2001-02-02 2003-10-09 Bland Jeffrey S. Medical composition for balancing bodily processes
EP1837030A1 (fr) * 2006-03-09 2007-09-26 INDENA S.p.A. Complexes phospholipidiques de curcumin ayant une biodisponibilité améliorée
WO2017202939A1 (fr) * 2016-05-27 2017-11-30 Nestec S.A. Composition nutritionnelle pour le traitement ou la prévention de la diminution de la mobilité

Also Published As

Publication number Publication date
FR3082425A1 (fr) 2019-12-20

Similar Documents

Publication Publication Date Title
MA55022A (fr) Compositions comprenant de la 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) pour une utilisation dans le traitement de troubles mentaux
CL2018001007A1 (es) Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538).
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
BR112017001339A2 (pt) método, pasta de cimento e sistema
MA52971A (fr) Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
BR112015019264A2 (pt) composições farmacêuticas para o tratamento de helicobacter pylori
FR3073140B1 (fr) Composition pour ameliorer la sante des animaux d'elevage
MX2020012800A (es) Cannabinoides y usos de los mismos.
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
FR3082425B1 (fr) Composition pour utilisation dans le traitement de l'osteopenie et / ou de l'osteoporose
FR3088542B1 (fr) Composition cicatrisante comprenant une eau électrolysée
FR3078628B1 (fr) Composition comestible sous forme de gelule pour la prevention de troubles de l’humeur
FR3072973B1 (fr) Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
BR112017023494A2 (pt) sistema de distribuição para distribuir um sistema de regeneração do esmalte
PE20171059A1 (es) Composiciones de triptamidas y sus metodos de uso
MA42419A (fr) Méthode de traitement de l'encéphalopathie hépatique
MA49635A (fr) Compositions comprenant du darunavir, du cobicistat, de l'emtricitabine et du ténofovir alafénamide pour une utilisation dans le traitement du vih
TN2018000055A1 (en) COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE LA HMG-CoA REDUCTASE ET UN INHIBITEUR ECA.
BR112016019002A2 (pt) composições para a prevenção e/ou o tratamento de patologias associadas a alfa-glicosidase
FR3034670B1 (fr) Nouvelle utilisation du facteur von willebrand

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20191220

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

TP Transmission of property

Owner name: EOS LABORATORY SRL, BE

Effective date: 20210902

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6